Role of oral teriflunomide in the management of multiple sclerosis

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 539-553

  Tanasescu, Radu ^a,b   Evangelou, Nikos ^a   Constantinescu, Cris S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Clinical trials; Multiple sclerosis; Oral drugs; Teriflunomide

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LAQUINIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PLACEBO; TERIFLUNOMIDE; WARFARIN;

ABDOMINAL PAIN; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ATRIOVENTRICULAR BLOCK; BACKACHE; BRADYCARDIA; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FLUSHING; FOOD; FOOD DRUG INTERACTION; HAIR THINNING; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFECTION; LEIOMYOMA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MENOMETRORRHAGI; METRORRHAGIA; MONOTHERAPY; MOUTH ULCER; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SPONTANEOUS ABORTION; THORAX PAIN; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 84876518370     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S31248     Document Type: Review

References (82)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648): 1502-1517.
2. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13(7):507-514.
3. Evangelou N. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: yes. Mult Scler. 2012;18(12):1680-1681.
4. Polman CH, Reingold SC, Banwell B, etal. Diagnostic criteria for multiple sclerosis: 2010revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
5. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2012; 25 Suppl:S11-S19.
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
7. Giovannoni G, Comi G, Cook S, etal. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426.
8. Kappos L, Radue EM, O'Connor P, etal. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
9. Cohen JA, Barkhof F, Comi G, etal. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415. Expert Opin Pharmacother. 2010;11(10):1777-1781.
10. Kappos L, Radue EW, O'Connor P, etal. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401.
11. Cohen JA, Barkhof F, Comi G, etal. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
12. Bruck W, Zamvil SS. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol. 2012;5(3):245-256.
13. Comi G, Jeffery D, Kappos L, etal. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
14. Limmroth V. Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. Nat Rev Neurol. 2013;9(1):8-10.
15. Gold R, Kappos L, Arnold DL, etal. Placebo-controlled phase 3study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
16. Fox RJ, Miller DH, Phillips JT, etal. Placebo-controlled phase 3study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
17. Gasperini C, Ruggieri S. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod, will change therapeutic paradigm approach. Drug Des Devel Ther. 2012;6: 175-186.
18. Fontoura P, Garren H. Multiple sclerosis therapies: molecular mechanisms and future. Results Probl Cell Differ. 2010;51:259-285.
19. Chan EC, New LS. In vitro metabolism of leflunomide by mouse and human liver microsomes. Drug Metab Lett. 2007;1(4):299-305.
20. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology. 2000;47(2-3): 273-289.
21. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J. 2008;15(2):62-68.
22. Posevitz V, Chudyka D, Kurth F, Wiendl H. Teriflunomide suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
23. Bar-Or A, Freedman MS, Kremenchutzky M, etal. Effect of teriflunomide on immune responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis: results from the TERIVA study. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
24. Korn T, Toyka K, Hartung HP, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain. 2001;124(Pt 9):1791-1802.
25. Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76(5):950-960.
26. Zeyda M, Poglitsch M, Geyeregger R, etal. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005;52(9): 2730-2739.
27. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 1993;334(2):161-164.
28. Migita K, Miyashita T, Ishibashi H, etal. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1β stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol. 2004;137(3):612-616.
29. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol. 1998;160(4):1581-1588.
30. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995;270(21):12398-12403.
31. Xu X, Williams JW, Gong H, Finnegan A, Chong AS. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol. 1996;52(4):527-534.
32. Hoskin DW, Taylor RM, Makrigiannis AP, James H, Lee TD. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int J Immunopharmacol. 1998; 20(9):505-513.
33. Nwankwo E, Allington DR, Rivey MP. Emerging oral immunomodulating agents-focus on teriflunomide for the treatment of multiple sclerosis. Degener Neurol Neuromuscul Dis. 2012;2:15-28.
34. Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol. 2002;169(6):3392-3399.
35. Deage V, Burger D, Dayer JM. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1β and metalloproteinases. Eur Cytokine Netw. 1998;9(4):663-668.
36. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol. 2012;142(1):49-56.
37. Miljkovic D, Samardzic T, Mostarica Stojkovic M, Stosic-Grujicic S, Popadic D, Trajkovic V. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes. Brain Res. 2001;889(1-2):331-338.
38. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol. 1999;127(7):1589-1596.
39. Jankovic V, Samardzic T, Stosic-Grujicic S, Popadic D, Trajkovic V. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. Cell Immunol. 2000;199(2):73-80.
40. Li L, Liu J, Zhang D, Jones C. Teriflunomide treatment of human monocyte-derived dendritic cells in vitro does not impair their maturation or ability to induce allogeneic T-cell responses. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
41. Bartlett RR, Dimitrijevic M, Mattar T, etal. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions. 1991;32(1-2):10-21.
42. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. March 20, 2013. [Epub ahead of print.]
43. LimsakunT, Menguy-Vacheron F. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of MS. Annual Meeting of the American Academy of Neurology (AAN); April 10-17, 2010; Toronto, ON, Canada.
44. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41(6):421-430.
45. Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ. 2002;325(7376):1333.
46. Turpault S, Mair S, Meng Z, Hochet A, Menguy-Vacheron F. Effect of teriflunomide on the pharmacodynamic and pharmacokinetic profiles of warfarin in healthy male subjects. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
47. Bergner R, Peters L, Schmitt V, Loffler C. Leflunomide in dialysis patients with rheumatoid arthritis-a pharmacokinetic study. Clin Rheumatol. 2013;32(2):267-270.
48. Merrill JE, Hanak S, Pu SF, etal. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol. 2009;256(1):89-103.
49. O'Connor PW, Li D, Freedman MS, etal. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900.
50. O'Connor PW, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Traboulsee A. Oral teriflunomide is effective and well tolerated in multiple sclerosis with relapses: results of an open-label 144-week extension study. 22nd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; September 27-30, 2006; Madrid, Spain.
51. O'Connor P, Wolinsky JS, Confavreux C, etal. Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomisation. Fifth Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; October 19-22, 2011; Amsterdam, The Netherlands.
52. Confavreux C, Li DK, Freedman MS, etal. Long-term follow-up of a phase 2study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18(9): 1278-1289.
53. O'Connor P, Wolinsky JS, Confavreux C, etal. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
54. Miller AE, O'Connor P, Wolinsky JS, etal. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012;18(11):1625-1632.
55. Kappos L, Comi G, Confavreux C, etal. The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
56. Sanofi. Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated November 5, 2012]. Available from: http://clinicaltrials.gov/show/NCT00622700. NLM identifier: NCT00622700. Accessed March 1, 2013.
57. Freedman MS, Wolinsky JS, Wamil B, etal. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78(23):1877-1885.
58. Freedman M, Wolinsky JS, Frangin GA. Oral teriflunomide or placebo added to glatiramer acetate for 6months in patients with relapsing multiple sclerosis: safety and efficacy results. 62nd Annual Meeting of the American Academy of Neurology (AAN); April 10-17, 2010; Toronto, ON, Canada.
59. Sanofi. Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-β (TERACLES). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated February 21, 2013]. Available from: http://clinicaltrials.gov/show/NCT01252355. NLM identifier: NCT01252355. Accessed March 1, 2013.
60. Vermersch P, Czlonkowska A, Grimaldi L, etal. A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon β-1a in patients with relapsing multiple sclerosis. Fourth Cooperative Meeting of CMSC and ACTRIMS; May 30-Jun 2, 2012; San Diego, CA, USA.
61. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123-1134.
62. Rahmlow M, Shuster EA, Dominik J, etal. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol. 2008;65(11): 1538-1539.
63. Clifford DB, Ances B, Costello C, etal. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156-1164.
64. Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford). 2008;47(2):224-225.
65. Sawada T, Inokuma S, Sato T, etal. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069-1072.
66. Chambers CD, Johnson DL, Robinson LK, etal. Birth outcomes in women who have taken leflunomide during pregnancy. Arth Rheum. 2010;62(5):1494-1503.
67. Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001;63(2):106-112.
68. Comi G, Benzerdjeb H, Wang L, Truffinet P, O'Connor P. Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
69. Wiese MD, Schnabl M, O'Doherty C, etal. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R163.
70. Kieseier B, Benamor M, Benzerdjeb H, Stuve O. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database. 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS); October 10-13, 2012; Lyon, France.
71. Freedman MS, Confavreux C, Comi G, etal. Hair thinning associated with teriflunomide therapy is manageable. Fourth Cooperative Meeting of CMSC and ACTRIMS; May 30-Jun 2, 2012; San Diego, CA, USA.
72. Balak DM, Hengstman GJ, Cakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012;18(12):1705-1717.
73. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10(11):1026-1034.
74. BioTrends Research Group. TreatmentTrends®: Multiple Sclerosis (US) 2012. Exton, PA: BioTrends Research Group; 2012. Available from: http://bio-trends.com/Images---Files/Products-and-Services/Products/TT-Report-Overviews/2011-Report-Overviews/TreatmentTrends/TreatmentTrends-Multiple-Sclerosis-in-the-US-1-5-1.aspx. Accessed March 22, 2013.
75. BioTrends Research Group. PatientTrends®: Multiple Sclerosis (US) 2012. Exton, PA: BioTrends Research Group; 2012. Available from: http://bio-trends.com/Images---Files/Products-and-Services/Products/TT-Report-Overviews/2011-Report-Overviews/PatientTrends/PatientTrends-Multiple-Sclerosis-1-17-12.aspx. Accessed March 22, 2013.
76. O'Connor P, Briggs A, Carita P, Bego-Le-Bagousse G. Impact on health-related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysis. Annual Meeting of the European Neurological Society (ENS); June 9-12, 2012; Prague, Czech Republic.
77. Vermersch P, Czlonkowska A, Grimaldi L, etal. Evaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon β-1a in patients with relapsing multiple sclerosis. Annual Meeting of the European Neurological Society (ENS); June 9-12, 2012; Prague, Czech Republic.
78. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75-84.
79. Noyes K, Bajorska A, Chappel A, etal. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011;77(4):355-363.
80. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V. Observational studies: propensity score analysis of non-randomized data. Int MS J. 2009;16(3):90-97.
81. He D, Xu Z, Dong S, etal. Teriflunomide for multiple sclerosis [review]. Cochrane Database Syst Rev. 2012;12:CD009882.
82. Freedman MS, Wolinsky JS, Byrnes WJ, etal. Oral teriflunomide or placebo added to interferon beta for months in patients with relapsing multiple sclerosis: safety and efficacy results. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); September 9-12, 2009; Dusseldorf, Germany.